TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
15 déc. 2017 04h00 HE
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker statusZEJULA is the only PARP inhibitor to...
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
28 nov. 2017 08h00 HE
|
TESARO, Inc.
VARUBI injectable emulsion features ready-to-use, single-dose vialNo saline, reconstitution or mixing is required to utilize VARUBI IVNew formulation offers healthcare providers flexibility in their...
TESARO Announces Participation in Two Investor Conferences
22 nov. 2017 16h05 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO Secures $500 Million Non-Dilutive Term Loan Financing
21 nov. 2017 08h00 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement...
TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year®
20 nov. 2017 08h00 HE
|
TESARO, Inc.
WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley,...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
20 nov. 2017 07h00 HE
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...
TESARO Announces Third-Quarter 2017 Operating Results
07 nov. 2017 16h05 HE
|
TESARO, Inc.
ZEJULA® was the most prescribed PARP inhibitor in U.S. with Q3 net sales of $39.4 millionPositive CHMP opinion issued for ZEJULA in E.U.; commercial launch anticipated to begin by year-endExpansion of...
TESARO Announces U.S. FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
25 oct. 2017 19h15 HE
|
TESARO, Inc.
VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...
TESARO to Announce Third-Quarter 2017 Financial Results on November 7, 2017
24 oct. 2017 16h15 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 24, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S....
TESARO Announces Participation at Two Investor Conferences
23 oct. 2017 16h15 HE
|
TESARO, Inc.
WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....